Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study

Plain-language summary

Published 2023 in J Clin Endocrinol Metab, this work by Pencina KM and collaborators tackles a specific question within science-focused NMN/NAD+ research.

Key findings reported by the authors

• Human study published in J Clin Endocrinol Metab (2023) examining Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Olde...
• Provides clinical-grade evidence on NAD+/NMN-related outcomes in human participants
• First author: Pencina KM; cited frequently in NMN supplementation discussions

What this means for Malaysian buyers

For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the moderate end of the evidence spectrum. Moderate-tier evidence usually means a small human trial or a well-designed mouse study; helpful for hypothesis-building but not for hard recommendations. Findings here are most directly relevant to science decisions. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.